Long-Term Use of Acetaminophen, Aspirin, and Other Nonsteroidal Anti-Inflammatory Drugs and Risk of Hematologic Malignancies: Results From the Prospective Vitamins and Lifestyle (VITAL) Study Several ...

Background More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 ...

or on the link below. The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing ...

Using the Shiny method, a more nuanced approach to meta-analysis, investigators determined that enfortumab vedotin plus pembrolizumab outperforms chemotherapy-based regimens for urothelial carcinoma.

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes. Among patients with advanced urothelial carcinoma who ...

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients. Primary urothelial cancer has variable ...

Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer. Increases in circulating tumor DNA fraction ...

BARCELONA, Spain — Health-related quality of life (HRQoL) is not further compromised by the addition of nivolumab (Opdivo) immunotherapy to first-line cisplatin-based chemotherapy in patients with ...

In a phase 3 trial, more deaths due to adverse events were reported in the Trodelvy arm compared with the chemotherapy arm. Gilead has made the decision to withdraw the accelerated approval of ...

Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV ™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) ...